{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:07:14Z","timestamp":1789204034071,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":86,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_851","type":"book-chapter","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:23:10Z","timestamp":1789201390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamics of Boronic Acids and Boronates"],"prefix":"10.1007","author":[{"given":"Alina","family":"Barquet-Nieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice D.","family":"Farf\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Mayorga-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J.","family":"Segura-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Soriano-Urs\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","volume":"19","author":"T Akama","year":"2009","unstructured":"Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19:2129\u20132132. https:\/\/doi.org\/10.1016\/j.bmcl.2009.03.007","journal-title":"Bioorg Med Chem Lett"},{"key":"851_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.17179\/excli2022-5653","volume":"22","author":"M Alwahsh","year":"2023","unstructured":"Alwahsh M, Farhat J, Talhouni S, Hamadneh L, Hergenr\u00f6der R (2023) Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J 22:146\u2013168. https:\/\/doi.org\/10.17179\/excli2022-5653","journal-title":"EXCLI J"},{"key":"851_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17425255.2019.1621839","volume":"15","author":"M Baljevic","year":"2019","unstructured":"Baljevic M, Orlowski RZ (2019) Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 15:459\u2013473. https:\/\/doi.org\/10.1080\/17425255.2019.1621839","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"851_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/ar300130w","volume":"46","author":"SD Bull","year":"2013","unstructured":"Bull SD, Davidson MG, van den Elsen JM, Fossey JS, Jenkins AT, Jiang YB, Kubo Y, Marken F, Sakurai K, Zhao J, James TD (2013) Exploiting the reversible covalent bonding of boronic acids: recognition, sensing, and assembly. Acc Chem Res 46:312\u2013326. https:\/\/doi.org\/10.1021\/ar300130w","journal-title":"Acc Chem Res"},{"key":"851_CR5","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/AAC.02260-16","volume":"61","author":"ST Cahill","year":"2017","unstructured":"Cahill ST, Cain R, Wang DY, Lohans CT, Wareham DW, Oswin HP, Mohammed J, Spencer J, Fishwick CW, McDonough MA, Schofield CJ, Brem J (2017) Cyclic boronates inhibit all classes of \u03b2-lactamases. Antimicrob Agents Chemother 61:e02260\u2013e02216. https:\/\/doi.org\/10.1128\/AAC.02260-16","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67141-5","volume":"17","author":"S Chatterjee","year":"2026","unstructured":"Chatterjee S, Chowdhury A, Verma N, Basa S, Tripathi NM, Gour V, Rai V, Bandypadhyay (2026) An efficient method for site-selective boronation of peptides and proteins applied in magnified bacterial imaging. Nat Commun 17:454. https:\/\/doi.org\/10.1038\/s41467-025-67141-5","journal-title":"Nat Commun"},{"key":"851_CR7","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1039\/D1TA02308J","volume":"9","author":"SG Cho","year":"2021","unstructured":"Cho SG, Hwang SY, Oh DX, Park JY (2021) Recent progress in self-healing polymers and hydrogels based on reversible dynamic B-O bonds: boronic\/boronate esters, borax and benzoxaborole. J Mater Chem A 9:14630\u201314655. https:\/\/doi.org\/10.1039\/D1TA02308J","journal-title":"J Mater Chem A"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/17460441.2012.717530","volume":"7","author":"L Ciani","year":"2012","unstructured":"Ciani L, Ristori S (2012) Boron as a platform for new drug design. Expert Opin Drug Discov 7:1017\u20131027. https:\/\/doi.org\/10.1517\/17460441.2012.717530","journal-title":"Expert Opin Drug Discov"},{"key":"851_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/1091581814545245","volume":"33","author":"V Ciaravino","year":"2014","unstructured":"Ciaravino V, Coronado D, Lanphear C, Shaikh I, Ruddock W, Chanda S (2014) Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies. Int J Toxicol 33:419\u2013427. https:\/\/doi.org\/10.1177\/1091581814545245","journal-title":"Int J Toxicol"},{"key":"851_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26113309","volume":"26","author":"PS Coghi","year":"2021","unstructured":"Coghi PS, Zhu Y, Xie H, Hosmane NS, Zhang Y (2021) Organoboron compounds: effective antibacterial and antiparasitic agents. Molecules 26:3309. https:\/\/doi.org\/10.3390\/molecules26113309","journal-title":"Molecules"},{"key":"851_CR11","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1021\/jm800390n","volume":"51","author":"BA Connolly","year":"2008","unstructured":"Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, Wu W, Liu Y, Maw H, Zhou Y, Li Y, Jin Z, Sudmeier JL, Lai JH, Bachovchin WW (2008) Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 51:6005\u20136013. https:\/\/doi.org\/10.1021\/jm800390n","journal-title":"J Med Chem"},{"key":"851_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4155\/fmc.13.38","volume":"5","author":"BC Das","year":"2013","unstructured":"Das BC, Thapa P, Karki R, Schinke C, Das S, Kambhampati S, Banerjee SK, Van Veldhuizen P, Verma A, Weiss LM, Evans T (2013) Boron chemicals in diagnosis and therapeutics. Future Med Chem 5:653\u2013676. https:\/\/doi.org\/10.4155\/fmc.13.38","journal-title":"Future Med Chem"},{"key":"851_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092615","volume":"27","author":"BC Das","year":"2022","unstructured":"Das BC, Nandwana NK, Das S, Nandwana V, Shareef MA, Das Y, Saito M, Weiss LM, Almaguel F, Hosmane NS, Evans T (2022) Boron chemicals in drug discovery and development: synthesis and medicinal. Molecules 27:2615. https:\/\/doi.org\/10.3390\/molecules27092615","journal-title":"Molecules"},{"key":"851_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121660","volume":"17","author":"N Dayal","year":"2024","unstructured":"Dayal N, Chaudhuri R, Yeboah KS, Brauer NR, Sintim HO (2024) Boronic acid-containing 3H-pyrazolo[4,3-f] quinoline compounds as dual CLK\/ROCK inhibitors with anticancer properties. Pharmaceuticals (Basel) 17:1660. https:\/\/doi.org\/10.3390\/ph17121660","journal-title":"Pharmaceuticals (Basel)"},{"key":"851_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.132057","volume":"1252","author":"B Dhawan","year":"2022","unstructured":"Dhawan B, Akhter G, Hamid H, Kesharwani P, Sarwar AM (2022) Benzoxaboroles: new emerging and versatile scaffold with a plethora of pharmacological activities. J Mol Struct 1252:132057. https:\/\/doi.org\/10.1016\/j.molstruc.2021.132057","journal-title":"J Mol Struct"},{"key":"851_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nchem.2814","volume":"9","author":"DB Diaz","year":"2017","unstructured":"Diaz DB, Yudin AK (2017) The versatility of boron in biological target engagement. Nat Chem 9:731\u2013742. https:\/\/doi.org\/10.1038\/nchem.2814","journal-title":"Nat Chem"},{"key":"851_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060491","volume":"12","author":"A Fantini","year":"2020","unstructured":"Fantini A, Demurtas A, Nicoli S, Padula C, Pescina S, Santi P (2020) In vitro skin retention of crisaborole after topicala. Pharmaceutics 12:491. https:\/\/doi.org\/10.3390\/pharmaceutics12060491","journal-title":"Pharmaceutics"},{"key":"851_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00044-023-03065-3","volume":"32","author":"Faridoon","year":"2023","unstructured":"Faridoon, Ng R, Zhang G, Li JJ (2023) An update on the discovery and development of reversible covalent inhibitors. Med Chem Res 32:1039\u20131062. https:\/\/doi.org\/10.1007\/s00044-023-03065-3","journal-title":"Med Chem Res"},{"key":"851_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","volume":"179","author":"GFS Fernandes","year":"2019","unstructured":"Fernandes GFS, Denny WA, Dos Santos JL (2019) Boron in drug design: recent advances in the development of new therapeutic agents. Eur J Med Chem 179:791\u2013804. https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.092","journal-title":"Eur J Med Chem"},{"issue":"19","key":"851_CR20","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","volume":"586","author":"YR Freund","year":"2012","unstructured":"Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y (2012) Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 586(19):3410\u20133414. https:\/\/doi.org\/10.1016\/j.febslet.2012.07.058","journal-title":"FEBS Lett"},{"key":"851_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121798","volume":"18","author":"MB Frooman","year":"2025","unstructured":"Frooman MB, Deb MK, Peters J, Leggett S, Sanghai N, Rizvi NZ, Atukorallaya D, Tranmer GK (2025) Recent advancements in the diversification and applications of boron-containing compounds in medicinal chemistry. Pharmaceuticals (Basel) 18:1798. https:\/\/doi.org\/10.3390\/ph18121798","journal-title":"Pharmaceuticals (Basel)"},{"key":"851_CR22","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2174\/0929867321666140601200803","volume":"21","author":"H Fu","year":"2014","unstructured":"Fu H, Fang H, Sun J, Wang H, Liu A, Sun J, Wu Z (2014) Boronic acid-based enzyme inhibitors: a review of recent progress. Curr Med Chem 21:3271\u20133280. https:\/\/doi.org\/10.2174\/0929867321666140601200803","journal-title":"Curr Med Chem"},{"key":"851_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/13543776.2025.2576513","volume":"35","author":"S Giovannuzzi","year":"2025","unstructured":"Giovannuzzi S, Nocentini A, Supuran CT, Winum JY (2025) Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019\u20132024). Expert Opin Ther Pat 35:1241\u20131261. https:\/\/doi.org\/10.1080\/13543776.2025.2576513","journal-title":"Expert Opin Ther Pat"},{"key":"851_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013691118","volume":"118","author":"BJ Graham","year":"2021","unstructured":"Graham BJ, Windsor IW, Gold B, Raines RT (2021) Boronic acid with high oxidative stability and utility in biological contexts. Proc Natl Acad Sci USA 118:e2013691118. https:\/\/doi.org\/10.1073\/pnas.2013691118","journal-title":"Proc Natl Acad Sci USA"},{"key":"851_CR25","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1021\/acs.chemrev.3c00663","volume":"124","author":"RJ Grams","year":"2024","unstructured":"Grams RJ, Santos WL, Scorei IR, Abad-Garc\u00eda A, Rosenblum CA, Bita A, Cerecetto H, Vi\u00f1as C, Soriano-Urs\u00faa MA (2024) The rise of boron-containing compounds: advancements in synthesis, medicinal chemistry, and emerging pharmacology. Chem Rev 124:2441\u20132511. https:\/\/doi.org\/10.1021\/acs.chemrev.3c00663","journal-title":"Chem Rev"},{"key":"851_CR26","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-18","volume":"63","author":"DC Griffith","year":"2019","unstructured":"Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN (2019) Pharmacokinetics\/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrob Agents Chemother 63:e01659\u2013e01618. https:\/\/doi.org\/10.1128\/AAC.01659-18","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","volume":"14","author":"M Groll","year":"2006","unstructured":"Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14:451\u2013456. https:\/\/doi.org\/10.1016\/j.str.2005.11.019","journal-title":"Structure"},{"key":"851_CR28","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1021\/acsptsci.5c00238","volume":"8","author":"YM Guo","year":"2025","unstructured":"Guo YM, Cui Y, Yang L, Wang XQ (2025) Recent development of boron-containing small-molecule anticancer agents. ACS Pharmacol Transl Sci 8:2384\u20132400. https:\/\/doi.org\/10.1021\/acsptsci.5c00238","journal-title":"ACS Pharmacol Transl Sci"},{"key":"851_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/09546634.2017.1329510","volume":"29","author":"AK Gupta","year":"2018","unstructured":"Gupta AK, Hall S, Zane LT, Lipner SR, Rich P (2018) Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. J Dermatolog Treat 29:44\u201348. https:\/\/doi.org\/10.1080\/09546634.2017.1329510","journal-title":"J Dermatolog Treat"},{"key":"851_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104873","volume":"121","author":"N Hadrup","year":"2021","unstructured":"Hadrup N, Frederiksen M, Sharma AK (2021) Toxicity of boric acid, borax and other boron containing compounds: a review. Regul Toxicol Pharmacol 121:104873. https:\/\/doi.org\/10.1016\/j.yrtph.2021.104873","journal-title":"Regul Toxicol Pharmacol"},{"key":"851_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/3527606548","volume-title":"Boronic acids: preparation and applications in organic synthesis and medicine","year":"2005","unstructured":"Hall DG (ed) (2005) Boronic acids: preparation and applications in organic synthesis and medicine. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 1\u2013549. https:\/\/doi.org\/10.1002\/3527606548"},{"key":"851_CR32","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1128\/AAC.02058-12","volume":"57","author":"V Hernandez","year":"2013","unstructured":"Hernandez V, Cr\u00e9pin T, Palencia A, Cusack S, Akama T, Baker SJ, Bu W, Feng L, Freund YR, Liu L, Meewan M, Mohan M, Mao W, Rock FL, Sexton H, Sheoran A, Zhang Y, Zhang YK, Zhou Y, Nieman JA, Anugula MR, Keramane e M, Savariraj K, Reddy DS, Sharma R, Subedi R, Singh R, O'Leary A, Simon NL, De Marsh PL, Mushtaq S, Warner M, Livermore DM, Alley MR, Plattner JJ (2013) Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother 57:1394\u20131403. https:\/\/doi.org\/10.1128\/AAC.02058-12","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585\u2013598. https:\/\/doi.org\/10.1038\/nrc2189","journal-title":"Nat Rev Cancer"},{"key":"851_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13060472","volume":"13","author":"T Hillyer","year":"2024","unstructured":"Hillyer T, Shin WS (2024) Meropenem\/vaborbactam\u2013A mechanistic review for insight into future development of combinational therapies. Antibiotics (Basel) 13:472. https:\/\/doi.org\/10.3390\/antibiotics13060472","journal-title":"Antibiotics (Basel)"},{"key":"851_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep02475","volume":"3","author":"QH Hu","year":"2013","unstructured":"Hu QH, Liu RJ, Fang ZP, Zhang J, Ding YY, Tan M, Wang M, Pan W, Zhou HC, Wang ED (2013) Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci Rep 3:2475. https:\/\/doi.org\/10.1038\/srep02475","journal-title":"Sci Rep"},{"key":"851_CR36","unstructured":"Jakubowiak JA (2012) Study of combination therapy with VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma. Identifier: NCT00135187 https:\/\/clinicaltrials.gov\/study\/NCT00135187. Accessed 26 June 2026"},{"key":"851_CR37","first-page":"390","volume":"15","author":"K Jarnagin","year":"2016","unstructured":"Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG (2016) Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol 15:390\u2013396. PMID: 27050693","journal-title":"J Drugs Dermatol"},{"key":"851_CR38","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.2147\/DDDT.S81944","volume":"9","author":"S Jinna","year":"2015","unstructured":"Jinna S, Finch J (2015) Spotlight on tavaborole for the treatment of onychomycosis. Drug Des Devel Ther 9:6185\u20136190. https:\/\/doi.org\/10.2147\/DDDT.S81944","journal-title":"Drug Des Devel Ther"},{"key":"851_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2024.2305833","volume":"39","author":"L Koll\u00e1r","year":"2024","unstructured":"Koll\u00e1r L, Grabrijan K, Hrast Rambaher M, Bozovi\u010dar K, Imre T, Ferenczy GG, Gobec S, Keser\u0171 GM (2024) Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents. J Enzyme Inhib Med Chem 39:2305833. https:\/\/doi.org\/10.1080\/14756366.2024.2305833","journal-title":"J Enzyme Inhib Med Chem"},{"key":"851_CR40","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S (2014) Proteasome inhibitors\u2014molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 18:947\u2013961. https:\/\/doi.org\/10.1111\/jcmm.12279","journal-title":"J Cell Mol Med"},{"key":"851_CR41","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70:1970\u20131980. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2766","journal-title":"Cancer Res"},{"key":"851_CR42","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2019","unstructured":"Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ (2019) Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem 63:2789\u20132801. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01518","journal-title":"J Med Chem"},{"key":"851_CR43","doi-asserted-by":"publisher","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN (2017) Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:e01443-17. https:\/\/doi.org\/10.1128\/AAC.01443-17","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR44","doi-asserted-by":"publisher","first-page":"e0057923","DOI":"10.1128\/aac.00579-23","volume":"67","author":"O Lomovskaya","year":"2023","unstructured":"Lomovskaya O, Tsivkovski R, Totrov M, Dressel D, Castanheira M, Dudley M (2023) New boronate drugs and evolving NDM-mediated beta-lactam resistance. Antimicrob Agents Chemother 67:e0057923. https:\/\/doi.org\/10.1128\/aac.00579-23","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/1203475420909794","volume":"24","author":"C Makins","year":"2020","unstructured":"Makins C, Sanghera R, Grewal PS (2020) Off-label therapeutic potential of crisaborole. J Cutan Med Surg 24:292\u2013296. https:\/\/doi.org\/10.1177\/1203475420909794","journal-title":"J Cutan Med Surg"},{"key":"851_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7547\/16-154","volume":"108","author":"B Markinson","year":"2018","unstructured":"Markinson B, Ghannoum M, Winter T, Rycerz A, Rock F, Gupta AK (2018) Examining the benefits of the boron-based mechanism of action and physicochemical properties of tavaborole in the treatment of onychomycosis. J Am Podiatr Med Assoc 108:12\u201319. https:\/\/doi.org\/10.7547\/16-154","journal-title":"J Am Podiatr Med Assoc"},{"key":"851_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1358\/dot.2017.53.10.2721815","volume":"53","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Walsh TJ (2017) Meropenem\/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections. Drugs Today (Barc) 53:521\u2013530. https:\/\/doi.org\/10.1358\/dot.2017.53.10.2721815","journal-title":"Drugs Today (Barc)"},{"key":"851_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/8755122519844507","volume":"35","author":"L McDowell","year":"2019","unstructured":"McDowell L, Olin B (2019) Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis. J Pharm Technol 35:172\u2013178. https:\/\/doi.org\/10.1177\/8755122519844507","journal-title":"J Pharm Technol"},{"key":"851_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK (2016) Spotlight on Ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217\u2013226. https:\/\/doi.org\/10.2147\/DDDT.S93602","journal-title":"Drug Des Devel Ther"},{"key":"851_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1021\/ACS.JMEDCHEM.6B01021","volume":"60","author":"C Nitsche","year":"2017","unstructured":"Nitsche C, Zhang L, Weigel LF, Schilz J, Graf D, Bartenschlager R, Hilgenfeld R, Klein CD (2017) Peptide-boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology. J Med Chem 60:511\u2013516. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.6B01021","journal-title":"J Med Chem"},{"key":"851_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","volume":"44","author":"AT Nunes","year":"2017","unstructured":"Nunes AT, Annunziata CM (2017) Proteasome inhibitors: structure and function. Semin Oncol 44:377\u2013380. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.004","journal-title":"Semin Oncol"},{"key":"851_CR52","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2147\/OTT.S49187","volume":"7","author":"M Offidani","year":"2014","unstructured":"Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P (2014) An evidence-based review of Ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther 7:1793\u20131800. https:\/\/doi.org\/10.2147\/OTT.S49187","journal-title":"Onco Targets Ther"},{"key":"851_CR53","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75:494\u2013503.e6. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"851_CR54","doi-asserted-by":"publisher","first-page":"e00398","DOI":"10.1128\/AAC.00398-20","volume":"64","author":"OA Pemberton","year":"2020","unstructured":"Pemberton OA, Tsivkovski R, Totrov M, Lomovskaya O, Chen Y (2020) Structural basis and binding kinetics of Vaborbactam in class A \u03b2-Lactamase inhibition. Antimicrob Agents Chemother 64(10):e00398\u2013e00320. https:\/\/doi.org\/10.1128\/AAC.00398-20","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09392-6","volume":"12","author":"M Perbandt","year":"2022","unstructured":"Perbandt M, Werner N, Prester A, Rohde H, Aepfelbacher M, Hinrichs W, Betzel C (2022) Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as \u03b2-lactamase inhibitors. Sci Rep 12:5510. https:\/\/doi.org\/10.1038\/s41598-022-09392-6","journal-title":"Sci Rep"},{"key":"851_CR56","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","volume":"52","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M (2018) In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme. Int J Antimicrob Agents 52:144\u2013150. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.02.021","journal-title":"Int J Antimicrob Agents"},{"key":"851_CR57","unstructured":"Pfizer (2017) Safety and efficacy study of a novel ointment to treat plaque type psoriasis. Identifier: NCT00759161. https:\/\/clinicaltrials.gov\/study\/NCT00759161. Accessed 26 June 2026"},{"key":"851_CR58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88\u201395. https:\/\/doi.org\/10.4049\/jimmunol.171.1.88","journal-title":"J Immunol"},{"key":"851_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112270","volume":"195","author":"J Plescia","year":"2020","unstructured":"Plescia J, Moitessier N (2020) Design and discovery of boronic acid drugs. Eur J Med Chem 195:112270. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112270","journal-title":"Eur J Med Chem"},{"key":"851_CR60","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1167\/iovs.06-1147","volume":"48","author":"V Poulaki","year":"2007","unstructured":"Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N (2007) The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci 48:4706\u20134719. https:\/\/doi.org\/10.1167\/iovs.06-1147","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"851_CR61","unstructured":"Richardson PG (2019) Bortezomib (Velcade) in patients with untreated multiple myeloma. Identifier: NCT00153920. https:\/\/clinicaltrials.gov\/study\/NCT00153920. Accessed 26 June 2026"},{"key":"851_CR62","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blad\u00e9 J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"key":"851_CR63","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1126\/science.1142189","volume":"316","author":"FL Rock","year":"2007","unstructured":"Rock FL, Mao W, Yaremchuk A, Tukalo M, Cr\u00e9pin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759\u20131761. https:\/\/doi.org\/10.1126\/science.1142189","journal-title":"Science"},{"key":"851_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrd1959","volume":"5","author":"I S\u00e1nchez-Serrano","year":"2006","unstructured":"S\u00e1nchez-Serrano I (2006) Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov 5:107\u2013114. https:\/\/doi.org\/10.1038\/nrd1959","journal-title":"Nat Rev Drug Discov"},{"key":"851_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26094182","volume":"26","author":"N Santi","year":"2025","unstructured":"Santi N, Piccirilli A, Corsini F, Taracila MA, Perilli M, Bonomo RA, Fini F, Prati F, Caselli E (2025) Discovery of boronic acids-based \u03b2-lactamase inhibitors through in situ click chemistry. Int J Mol Sci 26:4182. https:\/\/doi.org\/10.3390\/IJMS26094182","journal-title":"Int J Mol Sci"},{"key":"851_CR66","unstructured":"Schenk R (2021) Study of dutogliptin in combination with Filgrastim in post-myocardial infarction. Identifier: NCT03486080. https:\/\/clinicaltrials.gov\/study\/NCT03486080. Accessed 26 June 2026"},{"issue":"6299","key":"851_CR67","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aaf8993","volume":"353","author":"J Schrader","year":"2016","unstructured":"Schrader J, Henneberg F, Mata RA, Tittmann K, Schneider TR, Stark H, Bourenkov G, Chari A (2016) The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science 353(6299):594\u2013598. https:\/\/doi.org\/10.1126\/science.aaf8993","journal-title":"Science"},{"key":"851_CR68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/0976-500X.171870","volume":"6","author":"N Sharma","year":"2015","unstructured":"Sharma N, Sharma D (2015) An upcoming drug for onychomycosis: tavaborole. J Pharmacol Pharmacother 6:236\u2013239. https:\/\/doi.org\/10.4103\/0976-500X.171870","journal-title":"J Pharmacol Pharmacother"},{"key":"851_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25184323","volume":"25","author":"MP Silva","year":"2020","unstructured":"Silva MP, Saraiva L, Pinto M, Sousa ME (2020) Boronic acids and their derivatives in medicinal chemistry: synthesis and biological applications. Molecules 25:4323. https:\/\/doi.org\/10.3390\/molecules25184323","journal-title":"Molecules"},{"key":"851_CR70","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.2174\/0929867326666190327154954","volume":"26","author":"MA Soriano-Urs\u00faa","year":"2019","unstructured":"Soriano-Urs\u00faa MA, Farf\u00e1n-Garc\u00eda ED, Geninatti-Crich S (2019) Turning fear of boron toxicity into coron-containing drug design. Curr Med Chem 26:5005\u20135018. https:\/\/doi.org\/10.2174\/0929867326666190327154954","journal-title":"Curr Med Chem"},{"key":"851_CR71","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.2174\/0109298673364996250507091821","volume":"32","author":"MA Soriano-Ursua","year":"2025","unstructured":"Soriano-Ursua MA, Jelliss P, Cordova-Chavez RI, Rodriguez-Vera D, Valenzuela-Schejtman Y, Gonzalez-Espinosa H, Martinez-Ceron S, Farfan-Garcia ED (2025) Trends on potential boron-containing drugs by advancements in ligand-protein crystal complexes. Curr Med Chem 32:8270\u20138297. https:\/\/doi.org\/10.2174\/0109298673364996250507091821","journal-title":"Curr Med Chem"},{"key":"851_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1089\/derm.2023.0112","volume":"35","author":"LF Stein Gold","year":"2024","unstructured":"Stein Gold LF, Tom WL, Shi V, Sanders P, Zang C, Vlahos B, Cha A (2024) Impact of crisaborole in treatment-experienced patients with mild-to-moderate atopic dermatitis. Dermatitis 35:84\u201391. https:\/\/doi.org\/10.1089\/derm.2023.0112","journal-title":"Dermatitis"},{"key":"851_CR73","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1021\/acs.accounts.9b00292","volume":"52","author":"A Stubelius","year":"2019","unstructured":"Stubelius A, Lee S, Almutairi A (2019) The chemistry of boronic acids in nanomaterials for drug delivery. Acc Chem Res 52:3108\u20133119. https:\/\/doi.org\/10.1021\/acs.accounts.9b00292","journal-title":"Acc Chem Res"},{"key":"851_CR74","doi-asserted-by":"publisher","first-page":"e01694","DOI":"10.1128\/AAC.01694-17","volume":"61","author":"D Sun","year":"2017","unstructured":"Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O (2017) Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61:e01694\u2013e01617. https:\/\/doi.org\/10.1128\/AAC.01694-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"851_CR75","first-page":"1419","volume":"7","author":"JB Sunwoo","year":"2001","unstructured":"Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7(5):1419\u20131428. PMID: 11350913","journal-title":"Clin Cancer Res"},{"key":"851_CR76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1248\/yakushi.21-00173-3","volume":"142","author":"T Watanabe","year":"2022","unstructured":"Watanabe T, Momose I (2022) Boronic acid as a promising class of chemical entity for development of clinical medicine for targeted therapy of cancer. Yakugaku Zasshi 142:145\u2013153. https:\/\/doi.org\/10.1248\/yakushi.21-00173-3","journal-title":"Yakugaku Zasshi"},{"key":"851_CR77","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","volume":"9","author":"E Wenzler","year":"2020","unstructured":"Wenzler E, Scoble PJ (2020) An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam. Infect Dis Ther 9:769\u2013784. https:\/\/doi.org\/10.1007\/s40121-020-00344-z","journal-title":"Infect Dis Ther"},{"key":"851_CR78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12154-013-0099-0","volume":"6","author":"GF Whyte","year":"2013","unstructured":"Whyte GF, Vilar R, Woscholski R (2013) Molecular recognition with boronic acids-applications in chemical biology. J Chem Biol 6:161\u2013174. https:\/\/doi.org\/10.1007\/s12154-013-0099-0","journal-title":"J Chem Biol"},{"key":"851_CR79","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1021\/acssensors.1c00462","volume":"6","author":"GT Williams","year":"2021","unstructured":"Williams GT, Kedge JL, Fossey JS (2021) Molecular boronic acid-based saccharide sensors. ACS Sens 6:1508\u20131528. https:\/\/doi.org\/10.1021\/acssensors.1c00462","journal-title":"ACS Sens"},{"key":"851_CR80","unstructured":"Winthrop KL (2026) Epetraborole in patients with mycobacterium Abscessus lung disease (REBOUND). Identifier: NCT07301320. https:\/\/clinicaltrials.gov\/study\/NCT07301320. Accessed 26 June 2026"},{"key":"851_CR81","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/med.10043","volume":"23","author":"W Yang","year":"2003","unstructured":"Yang W, Gao X, Wang B (2003) Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23:346\u2013368. https:\/\/doi.org\/10.1002\/med.10043","journal-title":"Med Res Rev"},{"key":"851_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1039\/c7md00552k","volume":"9","author":"F Yang","year":"2017","unstructured":"Yang F, Zhu M, Zhang J, Zhou H (2017) Synthesis of biologically active boron-containing compounds. Med Chem Comm 9:201\u2013211. https:\/\/doi.org\/10.1039\/c7md00552k","journal-title":"Med Chem Comm"},{"key":"851_CR83","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s11426-013-4981-y","volume":"56","author":"J Zhang","year":"2013","unstructured":"Zhang J, Zhu MY, Lin YN, Zhou HC (2013) The synthesis of benzoxaboroles and their applications in medicinal chemistry. Sci China Chem 56:1372\u20131381. https:\/\/doi.org\/10.1007\/s11426-013-4981-y","journal-title":"Sci China Chem"},{"key":"851_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105754","volume":"116","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yang S, Deng Z, Song H, Xie N, Tian Y, Qin S, Liu J, Guo Y, Wang D, Liu J, Wu C, Shen J, Ma S, Wang Y, Liu D (2025) Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-\u03b2-lactamases inhibitor. EBioMedicine 116:105754. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105754","journal-title":"EBioMedicine"},{"issue":"10","key":"851_CR85","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1021\/acschembio.5b00291","volume":"10","author":"H Zhao","year":"2015","unstructured":"Zhao H, Palencia A, Seiradake E, Ghaemi Z, Cusack S, Luthey-Schulten Z, Martinis S (2015) Analysis of the resistance mechanism of a Benzoxaborole inhibitor reveals insight into the Leucyl-tRNA synthetase editing mechanism. ACS Chem Biol 10(10):2277\u20132285. https:\/\/doi.org\/10.1021\/acschembio.5b00291","journal-title":"ACS Chem Biol"},{"key":"851_CR86","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.pt.2024.07.003","volume":"40","author":"M Zoltner","year":"2024","unstructured":"Zoltner M, Horn D, Field MC (2024) Pass the boron: benzoxaboroles as antiparasite drugs. Trends Parasitol 40:820\u2013828. https:\/\/doi.org\/10.1016\/j.pt.2024.07.003","journal-title":"Trends Parasitol"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:23:14Z","timestamp":1789201394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":86,"URL":"https:\/\/doi.org\/10.1007\/164_2026_851","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}